TEVA-AMIODARONE 200 MG
AMIODARONE HYDROCHLORIDE : 200 MG · DIN 02239835 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-AMIODARONE?
TEVA-AMIODARONE 200 MG contains AMIODARONE HYDROCHLORIDE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02239835, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Jun-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-AMIODARONE used for?
Treatment of documented life-threatening, recurrent ventricular arrhythmias (unstable VT, recurrent VF) unresponsive to other agents. Not for asymptomatic arrhythmias.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02239835 |
|---|---|
| Brand name | TEVA-AMIODARONE |
| Generic / active ingredient | AMIODARONE HYDROCHLORIDE : 200 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C01BD01 AMIODARONE |
| AHFS class | 24:04.04.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Jun-2010 |
| Original market date | 1999-03-29 00:00:00 |
How is it administered?
Initiation must be in-hospital. Loading phase involves higher doses (e.g., 400-600 mg/day) followed by maintenance. Doses should be the lowest effective amount.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text sections (refers to Part I Summary/Part II for full details).
How is it supplied?
Not explicitly detailed in the provided text sections (refers to Part II/III for full details).
Contraindications
Hypersensitivity to iodine; cardiogenic shock; severe sinus-node dysfunction; 2nd/3rd degree AV block; syncope from bradycardia (without pacemaker); hepatitis; thyroid dysfunction; lung disease.
Warnings and precautions
Potentially fatal toxicities: pulmonary toxicity, liver injury, and proarrhythmia. Requires hospitalization for loading. Long half-life leads to prolonged adverse effects and interactions.
Is AMIODARONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by JAMP PHARMA CORPORATION, last seen 20 Mar 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C01BD01 AMIODARONE. 12 of 35 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMIODARONE | 200 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385465 |
| AMIODARONE | 200 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02364336 |
| AMIODARONE HYDROCHLORIDE FOR INJECTION | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02242325 |
| AMIODARONE HYDROCHLORIDE FOR INJECTION, USP | 50 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02245248 |
| APO-AMIODARONE TABLETS | 200 MG | TABLET | APOTEX INC | MARKETED | DIN 02246194 |
| JAMP AMIODARONE | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02531844 |
| PMS-AMIODARONE | 100 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02292173 |
| PMS-AMIODARONE | 200 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02242472 |
| PRO-AMIODARONE - 200 | 200 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02309661 |
| RIVA-AMIODARONE | 200 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02247217 |
Who else supplies AMIODARONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMIODARONE appears in 722 registered pack listings across 9 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.